Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer (ROAR-A)

Herlev Hospital

Status and phase: Enrolling; Phase 2

Conditions: Anal Cancer; Anal Carcinoma; Anal Squamous Cell Carcinoma

Treatments: Radiation: online adaptive radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT05438836

H-21028093

Details and patient eligibility

About

A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Enrollment: 205 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Biopsy-verified anal cancer
• Eligible for curative intended radiotherapy
• Written and oral consent

Exclusion criteria

• Other malignant disease within the past 5 years (excluding basal cell carcinoma)

Trial design

205 participants in 1 patient group

Online adaptive radiotherapy

Description:

Daily online adaptive radiotherapy

Treatment:

Radiation: online adaptive radiotherapy